data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Monopar Therapeutics
(NASDAQ:MNPR)
$2.20
-0.16[-6.78%]
At close: Jul 6
$2.23
0.0300[1.36%]
PreMarket: 8:39AM EDT
Day High/Low- - -
52 Week High/Low1.7 - 6.98
Open / Close- / -
Float / Outstanding4.4M / 12.6M
Vol / Avg.- / 9.4K
Mkt Cap27.8M
P/E-
50d Avg. Price2.19
Div / Yield-
Payout Ratio-
EPS-0.19
Total Float4.4M

Monopar Therapeutics (NASDAQ:MNPR), Quotes and News Summary

Monopar Therapeutics (NASDAQ: MNPR)

Day High/Low- - -
52 Week High/Low1.7 - 6.98
Open / Close- / -
Float / Outstanding4.4M / 12.6M
Vol / Avg.- / 9.4K
Mkt Cap27.8M
P/E-
50d Avg. Price2.19
Div / Yield-
Payout Ratio-
EPS-0.19
Total Float4.4M
Benzinga - May 12, 2022, 8:07AM
Benzinga - Apr 20, 2022, 5:29PM
Benzinga - Mar 24, 2022, 8:08AM
Benzinga - Feb 15, 2022, 8:17AM
Benzinga - Dec 8, 2021, 8:04AM
Benzinga - Nov 12, 2021, 8:12AM
Benzinga - Nov 1, 2021, 6:27AM
Benzinga - Oct 27, 2021, 1:54PM
Benzinga - Oct 27, 2021, 8:23AM
Benzinga - Sep 16, 2021, 8:06AM
Benzinga - Sep 14, 2021, 11:26AM
Benzinga - Sep 13, 2021, 8:06AM
Benzinga - Aug 12, 2021, 8:09AM
Benzinga - Aug 5, 2021, 8:28AM
Benzinga - Aug 3, 2021, 9:02AM
Sector: Health Care.Industry: Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-0.220-0.190 0.0300
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Monopar Therapeutics Questions & Answers

Q
How do I buy Monopar Therapeutics (MNPR) stock?
A

You can purchase shares of Monopar Therapeutics (NASDAQ: MNPR) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Monopar Therapeutics's (MNPR) competitors?
Q
What is the target price for Monopar Therapeutics (MNPR) stock?
A

The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on Monday, November 1, 2021. The analyst firm set a price target for 9.00 expecting MNPR to rise to within 12 months (a possible 309.09% upside). 1 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Monopar Therapeutics (MNPR)?
A

The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $2.2 last updated July 6, 2022, 8:00 PM UTC.

Q
Does Monopar Therapeutics (MNPR) pay a dividend?
A

There are no upcoming dividends for Monopar Therapeutics.

Q
When is Monopar Therapeutics (NASDAQ:MNPR) reporting earnings?
A

Monopar Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is Monopar Therapeutics (MNPR) going to split?
A

There is no upcoming split for Monopar Therapeutics.

Q
What sector and industry does Monopar Therapeutics (MNPR) operate in?
A

Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.